Skip to main content

Peer Review reports

From: Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study

Original Submission
5 Apr 2024 Submitted Original manuscript
12 Jun 2024 Reviewed Reviewer Report
16 Jul 2024 Reviewed Reviewer Report - Nicola Capasso
22 Jul 2024 Author responded Author comments - Mohammad Hossein Harirchian
Resubmission - Version 2
22 Jul 2024 Submitted Manuscript version 2
1 Aug 2024 Reviewed Reviewer Report
5 Aug 2024 Reviewed Reviewer Report - Nicola Capasso
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
6 Aug 2024 Editorially accepted
20 Aug 2024 Article published 10.1186/s12883-024-03793-y

You can find further information about peer review here.

Back to article page